Chronic Sinusitis: Updated Diagnostic and Treatment Strategies

Abstract

Chronic sinusitis, also referred to as chronic rhinosinusitis (CRS), remains a significant clinical challenge due to its multifactorial etiology, persistent symptomatology, and varying therapeutic responses. This review synthesizes recent research and guideline-based recommendations, offering clinicians a comprehensive update on epidemiology, pathophysiology, risk factors, clinical presentation, diagnostic approaches, and evolving management paradigms for CRS. Emphasis is placed on mechanism-driven understanding, the relevance of phenotyping and endotyping, and integration of emerging therapies into practice. Recommendations highlight the importance of individualized, evidence-based care for optimal patient outcomes.

Introduction

Chronic sinusitis is defined by persistent inflammation of the sinonasal mucosa lasting at least 12 weeks, often impairing quality of life and complicating comorbid conditions such as asthma. The landscape of CRS management has evolved with improved understanding of its heterogeneous nature, the impact of microbiome alterations, immunologic mechanisms, and the emergence of targeted therapies. This article reviews current evidence and clinical strategies for diagnosis and treatment, aiming to support healthcare professionals in delivering advanced, guideline-concordant care.

Epidemiology / Disease Burden

Chronic sinusitis affects an estimated 10-12% of the adult population in Western countries, with substantial impact on healthcare utilization and productivity. The disease contributes to millions of outpatient visits annually, significant direct and indirect costs, and is a leading cause of antibiotic prescriptions. CRS prevalence is higher among adults aged 30-60, with a slightly increased incidence in women. Comorbidities such as allergic rhinitis, asthma, and cystic fibrosis further amplify disease burden and complexity, underscoring the need for multidisciplinary management and ongoing research into population-specific risk profiles.

Pathophysiology

The pathogenesis of CRS involves a complex interplay of host, environmental, and microbial factors. Traditionally, CRS is subtyped as CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP), reflecting distinct immunopathological mechanisms. CRSwNP is characterized by type 2 (Th2) inflammation, eosinophilic infiltration, and elevated interleukins (IL-4, IL-5, IL-13), whereas CRSsNP may involve more neutrophilic and Th1/Th17-driven pathways. Disruption of the epithelial barrier, impaired mucociliary clearance, persistent bacterial biofilms, and altered sinonasal microbiota further sustain chronic inflammation and tissue remodeling. Emerging endotype classification helps guide mechanism-based therapies.

Risk Factors

Major risk factors for CRS include genetic susceptibility, atopy, environmental exposures (e.g., tobacco smoke, air pollution), anatomical variations (e.g., septal deviation, concha bullosa), and immune dysfunction. Recurrent upper respiratory tract infections, underlying immunodeficiencies, and comorbid conditions such as asthma and aspirin-exacerbated respiratory disease (AERD) increase susceptibility. Occupational irritant exposure and active smoking are modifiable contributors. Understanding patient-specific risk profiles facilitates preventive strategies and personalized management plans.

Clinical Features

Patients with CRS typically present with at least two of the following symptoms: nasal obstruction or congestion, mucopurulent nasal discharge, facial pain or pressure, and decreased sense of smell. Symptoms must persist for at least 12 weeks despite medical management. Additional findings may include postnasal drip, cough, fatigue, and halitosis. Physical examination often reveals mucosal edema, nasal polyps (in CRSwNP), purulent secretions, and tenderness overlying the sinuses. CRS significantly impairs quality of life, affecting sleep, cognitive function, and daily productivity.

Diagnosis

Diagnosis of CRS is primarily clinical, supported by history and endoscopic findings. Nasal endoscopy enables direct visualization of mucosal inflammation, polyps, and purulent discharge. Imaging, most commonly non-contrast computed tomography (CT) of the paranasal sinuses, is indicated for confirming diagnosis, assessing disease extent, surgical planning, or when complications are suspected. CT findings include mucosal thickening, opacification, air-fluid levels, and bony changes. Microbiological testing, allergy assessment, and immunological workup may be warranted in refractory or atypical cases. Differentiating CRS from acute rhinosinusitis, neoplasms, and other mimickers is essential for targeted management.

Treatment & Management

The cornerstone of CRS management is medical therapy, tailored to disease phenotype and severity. Intranasal corticosteroids (INCS) serve as first-line therapy for both CRSwNP and CRSsNP, reducing inflammation and polyp burden. Nasal saline irrigation is recommended as adjunctive therapy to enhance mucociliary clearance and symptom relief. Short courses of systemic corticosteroids may be indicated in severe or polyp-dominant cases, with careful risk-benefit assessment. Antibiotics are reserved for culture-proven or acute exacerbations with evidence of bacterial infection, given concerns over resistance. Management of comorbid allergic rhinitis and asthma is integral to holistic care.

Recent Advances / Emerging Therapies

Recent years have witnessed substantial progress in CRS treatment, notably the advent of biologic agents targeting type 2 inflammatory pathways. Monoclonal antibodies such as dupilumab (anti-IL-4Rα), mepolizumab (anti-IL-5), and omalizumab (anti-IgE) have demonstrated efficacy in reducing polyp size, symptom burden, and surgical need in CRSwNP patients with refractory disease. These targeted therapies are particularly beneficial for patients with comorbid asthma or AERD. Innovations in topical drug delivery, antimicrobial strategies targeting biofilms, and microbiome-based interventions are under active investigation, promising further personalization of CRS management.

Guideline Recommendations

Recent international guidelines, including those from the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS 2020) and the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), emphasize a stepwise, evidence-based approach. Initial therapy should focus on INCS and saline irrigation, with escalation to systemic therapies, antibiotics, or surgery in refractory cases. Endoscopic sinus surgery (ESS) is reserved for patients with persistent symptoms despite optimized medical therapy, offering symptomatic and quality-of-life improvement. The integration of biologics is recommended for severe CRSwNP with inadequate response to conventional modalities. Multidisciplinary care, shared decision-making, and regular follow-up are integral to achieving optimal outcomes.

Conclusion

Chronic sinusitis represents a prevalent, multifaceted disorder requiring nuanced diagnosis and individualized management. Advances in understanding pathophysiologic mechanisms, risk stratification, and targeted therapies have transformed the clinical approach, offering hope for improved patient outcomes. Ongoing research, adherence to guideline-directed care, and interdisciplinary collaboration remain essential to effectively address the evolving landscape of CRS. Clinicians are encouraged to adopt mechanism-based, patient-centered strategies, integrating emerging evidence and innovation in daily practice.